Nonadherence to oral medications for chronic conditions in breast cancer survivors

Journal of Oncology Practice

Volumn 12, Issue 8, 2016, Pages e800-e809

  Yang, Jingyan ^a   Neugut, Alfred I ^a   Wright, Jason D ^a   Accordino, Melissa ^a   Hershman, Dawn L ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; BONE DENSITY CONSERVATION AGENT; GASTROINTESTINAL AGENT; HYPOCHOLESTEROLEMIC AGENT; ORAL ANTIDIABETIC AGENT; PRESCRIPTION DRUG;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; EARLY CANCER; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; POLYPHARMACY; RETROSPECTIVE STUDY; THYROID DISEASE; ADOLESCENT; BREAST NEOPLASMS; HYPERLIPIDEMIAS; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; SURVIVOR; THYROID DISEASES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CHRONIC DISEASE; DIABETES MELLITUS; DRUG THERAPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; SURVIVORS; THYROID DISEASES; YOUNG ADULT;

EID: 84981719948     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2016.011742     Document Type: Article

References (44)

1. Berglund A, Wigertz A, Adolfsson J, et al: Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat 135: 281-289, 2012
2. Cho H, Mariotto AB, Mann BS, et al: Assessing non-cancer-related health status of US cancer patients: Other-cause survival and comorbidity prevalence. Am J Epidemiol 178:339-349, 2013
3. Edwards BK, Noone AM, Mariotto AB, et al: Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120:1290-1314, 2014
4. Read WL, Tierney RM, Page NC, et al: Differential prognostic impact of comorbidity. J Clin Oncol 22:3099-3103, 2004
5. American Cancer Society: Breast Cancer Facts & Figures 2013-2014. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf
6. Land LH, Dalton SO, Jensen MB, et al: Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 107:1901-1907, 2012
7. Land LH, Dalton SO, Jensen MB, et al: Impact of comorbidity on mortality: A cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. Breast Cancer Res Treat 131:1013-1020, 2012
8. Land LH, Dalton SO, Jørgensen TL, et al: Comorbidity and survival after early breast cancer: A review. Crit Rev Oncol Hematol 81:196-205, 2012
9. Mell LK, Jeong JH, Nichols MA, et al: Predictors of competing mortality in early breast cancer. Cancer 116:5365-5373, 2010
10. Yasmeen S, Chlebowski RT, Xing G, et al: Severity of comorbid conditions and early-stage breast cancer therapy: Linked SEER-Medicare data from 1993 to 2005. Cancer Med 2:526-536, 2013
11. Haque R, Prout M, Geiger AM, et al: Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care 20:86-92, 2014
12. Gibson K, O'Bryant CL: Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. J Oncol Pharm Pract 14:139-145, 2008
13. Carney JF, Davis J: Emerging bone health issues in women with breast cancer in Hawai'i. Hawaii Med J 66:164-166, 2007
14. Roberts R, Miller M, O'Callaghan M, et al: Bone health management of Australian breast cancer survivors receiving hormonal therapy. Intern Med J 45:1182-1185, 2015
15. Giani C, Fierabracci P, Bonacci R, et al: Relationship between breast cancer and thyroid disease: Relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 81:990-994, 1996
16. El-Serag HB, Sweet S, Winchester CC, et al: Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 63:871-880, 2014
17. Kalder M, Hadji P: Breast cancer and osteoporosis: Management of cancer treatment-induced bone loss in postmenopausal women with breast cancer. Breast Care (Basel) 9:312-317, 2014
18. Garner CN, Ganetzky R, Brainard J, et al.: Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery 142:806-813, 2007
19. Søgaard M, Thomsen RW, Bossen KS, et al: The impact of comorbidity on cancer survival: A review. Clin Epidemiol 5:3-29, 2013 (suppl 1)
20. Calip GS, Hubbard RA, Stergachis A, et al: Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24:75-85, 2015
21. Calip GS, Boudreau DM, Loggers ET: Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat 138:225-233, 2013
22. Zanders MM, Haak HR, van Herk-Sukel MP, et al: Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia 58:951-960, 2015
23. Shin DW, Park JH, Park JH, et al: Antihypertensive medication adherence in cancer survivors and its affecting factors: Results of a Korean population-based study. Support Care Cancer 19:211-220, 2010
24. Giordano SH, Lin YL, Kuo YF, et al: Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232-2239, 2012
25. Freeman JL, Zhang D, Freeman DH, et al: An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol 53:605-614, 2000
26. Nattinger AB, Laud PW, Bajorunaite R, et al: An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39:1733-1749, 2004
27. Gold HT, Do HT: Evaluation of three algorithms to identify incident breast cancer in Medicare claims data. Health Serv Res 42:2056-2069, 2007
28. Baldi I, Vicari P, Di Cuonzo D, et al: A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. J Clin Epidemiol 61:373-379, 2008
29. Hall AE, Paul C, Bryant J, et al: To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol 97:247-262, 2016
30. daCosta DiBonaventura M, Copher R, Basurto E, et al: Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits 7:386-396, 2014
31. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113:5401-5411, 2009
32. Balkrishnan R: Predictors of medication adherence in the elderly. Clin Ther 20:764-771, 1998
33. Tam-McDevitt J: Polypharmacy, aging, and cancer. Oncology (Williston Park) 22:1052-1055, 2008
34. LeBlanc TW, McNeil MJ, Kamal AH, et al: Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol 16:e333-e341, 2015
35. Neugut AI, Subar M, Wilde ET, et al: Association between prescription copayment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011
36. Kimmick G, Anderson R, Camacho F, et al: Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27:3445-3451, 2009
37. Atkins L, Fallowfield L: Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271-2276, 2006
38. Hershman DL, Tsui J, Meyer J, et al: The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst 106:dju319, 2014
39. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298:61-69, 2007
40. Johnson RE, Goodman MJ, Hornbrook MC, et al: The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care 35:1119-1131, 1997
41. Babazono A, Tsuda T, Yamamoto E, et al: Effects of an increase in patient copayments on medical service demands of the insured in Japan. Int J Technol Assess Health Care 19:465-475, 2003
42. Curkendall SM, Thomas N, Bell KF, et al: Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin 29:1275-1286, 2013
43. Kazerooni R, Bounthavong M, Watanabe JH: Association of copayment and statin adherence stratified by socioeconomic status. Ann Pharmacother 47:1463-1470, 2013
44. Nieuwlaat R, Wilczynski N, Navarro T, et al: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 11:CD000011, 2014